Fanotaprim

Catalog No. :
ACPZKJ796
CAS No. :
2120282-75-7
Molecular Formula :
C19H22N8O
Molecular Weight :
378.44

IUPAC Name:5-(4-(3-(2-methoxypyrimidin-5-yl)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine

Fanotaprim structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg98%$129.00Login to see priceIn stockInquiry
10mg98%$210.00Login to see priceIn stockInquiry
25mg98%$411.00Login to see priceIn stockInquiry
50mg98%$564.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameFanotaprim
IUPAC Name5-(4-(3-(2-methoxypyrimidin-5-yl)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine
Molecular FormulaC19H22N8O
Molecular Weight378.44
SMILESNC1=NC=C(N2CCN(C3=CC=CC(C4=CN=C(OC)N=C4)=C3)CC2)C(N)=N1
InChI KeyGUZBZPCNAJDYMO-UHFFFAOYSA-N
SynonymFanotaprim;CD-1,Inhibitor,Fanotaprim,mice,VYR 006,DHFR,VYR-006,inhibit,Antifolate,dhydrofolate,reductase,survival,toxoplasmosis,VYR006;Fanotaprim, 10 mM in DMSO
CAS No.2120282-75-7
PubChem CID134812633

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACPZKJ796 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCPEH789 route compound structure diagram
    ACCPEH789628692-15-9 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACPZKJ796 route product structure diagram
    ACPZKJ7962120282-75-7 In Stock
Inquiry

2. ACPZKJ796 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACVMHY731 route compound structure diagram
    ACVMHY73114001-66-2 In Stock
  4. Then
  5. ACPZKJ796 route product structure diagram
    ACPZKJ7962120282-75-7 In Stock
Inquiry

Comments (0)